LTI-2355

N/A

Report date: 2025/06/04 11:51:45
NME

Base Information

Drug NameLTI-2355
Drug Alias NameLTI-2355
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRein Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRein Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPost-Acute COVID-19 SyndromeIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A